Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492592 | 1.00 | IDO1 (0.53) | IDO1USP30P2RX7PDE2APTGDR2 | |
| SCHEMBL30970519 | 0.85 | IDO1 (0.53) | IDO1PDE2APTGDR2KIF11RXRA | |
| SCHEMBL195125 | 0.85 | IDO1 (0.53) | IDO1PDE2APTGDR2KIF11RXRA | |
| SCHEMBL18978864 | 0.83 | IDO1 (0.54) | IDO1USP30P2RX7PDE2ACA1 | |
| SCHEMBL24147012 | 0.81 | CES2 (0.42) | IDO1KIF11RXRARXRBRXRG | |
| SCHEMBL6902387 | 0.80 | RXRA (0.40) | IDO1PDE2AKIF11RXRARXRB | |
| SCHEMBL3827787 | 0.80 | IDO1 (0.37) | IDO1KIF11RXRARXRBRXRG | |
| SCHEMBL18602316 | 0.80 | IDO1 (0.40) | IDO1KIF11RXRARXRBRXRG | |
| SCHEMBL24146760 | 0.80 | AR (0.44) | IDO1KIF11CTSSSLC6A4 | |
| SCHEMBL7886912 | 0.80 | PIEZO1 (0.41) | IDO1KIF11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1740146-A | Prepn process of 2-fluoro-5-trifluoromethyl benzyl cyanide | DALIAN LUYUAN PHARMACEUTICAL I (CN) | 2006-03-01 | — | — | CN | claimed |
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2024-02-01 | — | — | US | disclosed |
| EP-4217065-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2023-08-02 | — | — | EP | disclosed |
| CN-116368112-A | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| CN-1740146-A | Prepn process of 2-fluoro-5-trifluoromethyl benzyl cyanide | DALIAN LUYUAN PHARMACEUTICAL I (CN) | 2006-03-01 | — | — | CN | disclosed |
| CN-1740146-A | Prepn process of 2-fluoro-5-trifluoromethyl benzyl cyanide | DALIAN LUYUAN PHARMACEUTICAL I (CN) | 2006-03-01 | — | — | CN | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6528657-B2 | For use in electroluminescence light emission element and can emit lights of various colors when an energy such as electric energy or electromagnetic energy is applied thereto | TAIHO INDUSTRIES CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | HIROSE ENGINEERING CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | IDO1 7/4885USP30 3982/4885P2RX7 2099/4885 |
| US-20030232824-A1 | Non-steroidal progesting | PGR, NR5A1, GPER1 | IDO1 3857/4885USP30 2254/4885P2RX7 3002/4885 |
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | IDO1 4521/4885USP30 2786/4885P2RX7 245/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | IDO1 54/4885USP30 3977/4885P2RX7 935/4885 |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | CBR3, AANAT, SIRT3 | IDO1 289/4885USP30 2130/4885P2RX7 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.